A large number of patients worldwide receive anticoagulant and antiplatelet agents, collectively known as antithrombotic agents. Several new anticoagulants and antiplatelet agents recently were approved for use. Gastroenterologists may be unfamiliar with the mechanism of action, indications for use, and pharmacokinetics of these newer drugs. In patients undergoing elective and urgent endoscopic procedures, clinicians must be familiar with these medications to optimize outcomes. When the decision is made to continue the newer antithrombotic agents for elective procedures, the clinician must understand the risk that these agents may impart on procedural-induced bleeding. Finally, it is important to understand how to manage these agents in the presence of acute gastrointestinal bleeding. In this article the use of newer antithrombotic agents is reviewed.
Keywords: AF; Anticoagulants/Administration and Dosage; Atrial Fibrillation; CrCl; DTI; DVT; DXI; Drug Administration Schedule; Drug Monitoring; ERCP; Endoscopy; FDA; FEIBA; FVII; Factor VII; Factor VIII inhibitor bypass activity; Food and Drug Administration; GI; Gastrointestinal; MI; PCC; PCI; PE; PT; TT; Thrombosis/Drug Therapy; aPTT; activated partial thromboplastin time; atrial fibrillation; creatinine clearance; deep venous thrombosis; direct factor X inhibitor; direct thrombin inhibitor; endoscopic retrograde cholangiopancreatography; gastrointestinal; myocardial infarction; percutaneous coronary intervention; prothrombin complex concentrate; prothrombin time; pulmonary embolism; rFVIIa; recombinant FVIIa; thrombin time.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.